Biotechnology Industry
Filter News
Found 38,155 articles
-
In a double data drop Thursday, AbbVie touted two clinical trial wins, for Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus.
-
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
3/24/2023
Humacyte, Inc. today announced financial results for the fourth quarter and year ended December 31, 2022, and highlighted recent corporate accomplishments.
-
Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
3/24/2023
Moderna, Inc. today announced that it will present its Vaccines Day for analysts and investors at 8:00 a.m. ET on Tuesday, April 11, 2023.
-
HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
3/24/2023
HiberCell today announced three pre-clinical poster presentations which will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.
-
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 9-0 that tofersen's effect on neurofilament light chain (NfL) could be a reasonable predictor of clinical benefit.
-
Wednesday, the FDA approved Cidara Therapeutics and Melinta Therapeutics’ Rezzayo (rezafungin) injection to treat candidemia and invasive candidiasis.
-
Novo Nordisk and Dewpoint Therapeutics have inked a deal to use the latter's biomolecular condensates discovery platform to treat insulin resistance and diabetic complications.
-
Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes
3/23/2023
Creative Medical Technology Holdings, Inc. announced that it filed an application with the U.S. Food and Drug Administration to receive Orphan Drug Designation for the treatment of Brittle Type 1 Diabetes using its ImmCelz® platform.
-
Valitor to Present at the Association for Research in Vision and Ophthalmology Annual Meeting
3/23/2023
Valitor, a biotechnology company engineering better medicines to conquer drug limitations, announced that two abstracts have been accepted for poster presentation at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting taking place April 23-27, 2023 in New Orleans, LA.
-
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference
3/23/2023
Ceapro Inc. announced that the abstract titled, “Reprogramming Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage Modulator for Lung Fibrosis,” has been accepted for a presentation at the American Thoracic Society International Conference to be held at the Walter E. Washington Convention Center in Washington, DC between May 19-24, 2023.
-
Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer
3/23/2023
Jasper Therapeutics, Inc. today announced the appointment of Daniel Adelman, M.D., as the company’s Acting Chief Medical Officer.
-
Sirona Biochem Announces Debenture Financing
3/23/2023
Sirona Biochem Corp. is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures.
-
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
3/23/2023
Evaxion Biotech A/S today announces that it has developed a new proprietary AI platform technology ObsERV™ to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy.
-
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
3/23/2023
Monte Rosa Therapeutics, Inc. today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors.
-
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
3/23/2023
Enveric Biosciences, Inc. today announced that it has entered into an agreement with Avance Clinical for its planned Phase 1 clinical trial of EB-373, the company’s lead candidate targeting the treatment of anxiety disorders.
-
Cambrium Launches NovaColl™: First Micro-Molecular & Skin-Identical Collagen Ingredient for Personal Care Industry
3/23/2023
Biotechnology company Cambrium has launched its first product: NovaColl™. It is the first micro-molecular & 100% skin-identical collagen specifically designed for premium personal care formulations.
-
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination
3/23/2023
Graf Acquisition Corp. IV and NKGen Biotech, Inc. announced that they have signed a non-binding letter of intent to pursue a business combination.
-
Aptose Reports Results for the Fourth Quarter and Full Year 2022
3/23/2023
Aptose Biosciences Inc. announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.
-
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines - March 23, 2023
3/23/2023
Moderna, Inc. and Generation Bio Co. today announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform.
-
Journey Biosciences Selected as First Company for StartUp Health's Type 1 Diabetes Moonshot
3/23/2023
Journey Biosciences announced that it has become the first company to receive a T1D Moonshot Fellowship in StartUp Health's T1D Moonshot, a bold new initiative to inspire, educate and empower founders and funders to ensure "that everyone with Type 1 diabetes has the tools and resources necessary to thrive."